Share This Article:

Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia

Abstract Full-Text HTML Download Download as PDF (Size:221KB) PP. 53-58
DOI: 10.4236/ojra.2012.23011    4,473 Downloads   8,050 Views   Citations

ABSTRACT

Objective: To investigate the clinical effect of rituximab (RTX) in the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: A total of 10 patients with progressive RA-ILD were enrolled into this 48-week, open-label treatment study. Treatment was with RTX at 1000 mg at day 1, day 15, and again at weeks 24 and 26, with concomitant methotrexate therapy. Results: The study included 4 men and 6 women. Of 7 evaluable patients at week 48, the diffusing capacity to carbon monoxide had worsened by at least 15% in 1 patient, was stable in 4 patients, and increased by >15% of baseline value in 2 patients. The forced vital capacity declined by at least 10% in 1 patient, was stable in 4 patients, and increased by at least 10% in 2 patients. High resolution computed tomo-graphy of the chest showed improvement in 1 patient, and was unchanged in 5. Three patients were withdrawn, one who had an infusion reaction at week 0, one at week 5 who was hospitalized for congestive heart failure at week 5 and who later died at week 32 of complications following a traumatic hip fracture, and one died at week 6 of possible pneumonia. Conclusions: In this pilot study of 10 patients with RA-ILD treated with RTX, measures of lung disease remained stable in the majority of study completers. Further research is needed to clarify whether this treatment has a role in management of RA-ILD.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

E. Matteson, T. Bongartz, J. Ryu, C. Crowson, T. Hartman and P. Dellaripa, "Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 2 No. 3, 2012, pp. 53-58. doi: 10.4236/ojra.2012.23011.

References

[1] C. Turesson, W. M. O’Fallon, C. S. Crowson, S. E. Gabriel and E. L. Matteson, “Extra-Articular Disease Manifestations in Rheumatoid Arthritis: Incidence Trends and Risk Factors over 46 Years,” Annals of the Rheumatic Diseases, Vol. 62, No. 8, 2003, pp. 722-727. doi:10.1136/ard.62.8.722
[2] T. Bongartz, C. Nannini, Y. F. Medina-Velasquez, S. J. Achenbach, C. S. Crowson, J. H. Ryu, R. Vassallo, S. E. Gabriel and E. L. Matteson, “Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 62, No. 5, 2010, pp. 1583-1591. doi:10.1002/art.27405
[3] C. Nannini, J. H. Ryu and E. L. Matteson, “Lung Disease in Rheumatoid Arthritis,” Current Opinion in Rheumatology, Vol. 20, No. 3, 2008, pp. 340-346.
[4] S. V. Kocheril, B. E. Appleton, E. C. Somers, E. A. Kazerooni, K. R. Flaherty, F. J. Martinez, et al., “Comparison of Disease Progression and Mortality of Connective Tissue Disease-Related Interstitial Lung Disease and Idiopathic Interstitial Pneumonia,” Arthritis & Rheumatism, Vol. 53, No. 2, 2005, pp. 549-557.
[5] K. Phillips, K. R. Flaherty, E. L. Matteson, T. Bongartz, J. Bathon, K. K. Brown and P. F. Dellaripa, “Interstitial Lung Disease in Rheumatoid Arthritis,” Current Rheu- matology Reviews, Vol. 6, No. 2, 2010, pp. 120-126.
[6] C. Turesson and E. L. Matteson, “Extraarticular Features of Rheumatoid Arthritis and Systemic Involvement,” In: M. C. Hochberg, A. J. Silman, J. S. Smolen, M. E. Weinblatt and M. H. Weisman, Eds., Rheumatology, 5th Edition, Mosby, Philadelphia, 2011, pp. 839-847.
[7] G. Raghu, H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr, K. K. Brown, et al., “An Official ATS/ERS/JRS/ ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines For Diagnosis and Management,” American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 7, 2011, pp. 788-782.
[8] W. A. Wallace, S. E. Howie, A. S. Krajewski and D. Lamb, “The Immunological Architecture of B-Lymphocyte Aggregates in Cryptogenic Fibrosing Alveolitis,” Journal of Pathology, Vol. 178, No. 3, 1996, pp. 323-329.
[9] S. R. Atkins, C. Turesson, J. L. Myers, H. D. Tazelaar, J. H. Ryu, E. L. Matteson, et al., “Morphologic and Quantitative Assessment of CD20+ B Cell Infiltrates in Rheumatoid Arthritis-Associated Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia,” Arthritis & Rheumatism, Vol. 54, No. 2, 2006, pp. 6635-6641.
[10] C. Turesson, E. L. Matteson, T. V. Colby, Z. Vuk-Pavlovic, R. Vassallo, C. M. Weyand, et al., “Increased CD4+ T cell Infiltrates in Rheumatoid Arthritis-Associated Interstitial Pneumonitis Compared with Idiopathic Interstitial Pneumonitis,” Arthritis & Rheumatism, Vol. 52, No. 1, 2005, pp. 73-79.
[11] P. Emery, R.Fleischmann, A. Filiowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, et al., “The Efficacy and Safety of Rituximab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results of a Phase IIB Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial,” Arthritis & Rheumatism, Vol. 54, No. 5, 2006, pp. 1390-1400. doi:10.1002/art.21778
[12] F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mc-Shane, J. F. Fries, N. S. Cooper, et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 31, No. 3, 1988, pp. 315-324. doi:10.1002/art.1780310302
[13] P. W. Jones, “The St George’s Respiratory Questionnaire,” Respiratory Medicine, Vol. 85, No. B, 1991, pp. 25-31.
[14] L. A. Saketkoo, E. L. Matteson, K. K. Brown, J. R. Seibold, V. Strand, P. Dellaripa, K. Flaherty, D. Huscher, D. Khanna, C. V. Oddis, K. Phillips, D. Pittrow, A. Wells, C. Denton, O. Distler, A. Fischer, O. Kowal-Bielecka, S. Mittoo and J. Swigris, “Developing Disease Activity and Response Criteria in Connective Tissue Disease-Related Interstitial Lung Disease,” The Journal of Rheumatology, Vol. 38, No. 7, 2011, pp. 1514-1518. doi:10.3899/jrheum.110281
[15] A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers and A. J. K. ?st?r, “Non-Infectious Pulmonary Toxicity of Rituximab: A Systematic Review,” Rheumatology, Vol. 51, No. 4, 2012, pp. 653-662. doi:10.1093/rheumatology/ker290
[16] H. Liote, F. Liote, B. Seroussi, C. Mayaud and J. Cadranel, “Rituximab-Induced Lung Disease: A Systematic Literature Review,” European Respiratory Journal, Vol. 35, No. 3, 2010, pp. 681-687. doi:10.1183/09031936.00080209

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.